drug_type
RELEVANT_DRUG
intervention_type
Viral vector therapeutic cancer vaccine
drug_description
IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD) is an adenoviral serotype 5 viral vector therapeutic cancer vaccine encoding HPV E6 and E7 antigens engineered with an endosomal/lysosomal targeting domain (ETSD) to enhance MHC I/II presentation, inducing a Th1-biased CD8+ and CD4+ T-cell response against HPV-expressing tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Papillomavirus Vaccines
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Injection
drug_mechanism_of_action
A non-replicating adenoviral serotype 5 vector delivers genes encoding HPV E6 and E7 fused to an endosomal/lysosomal targeting domain, enhancing MHC I/II antigen presentation in APCs and inducing a Th1-biased, HPV-specific CD8+ and CD4+ T-cell response to kill HPV-expressing tumor cells.
drug_name
IBRX-042
nct_id_drug_ref
NCT05976828